Title: Hereditary Diffuse Gastric Cancer (HDGC) and Prophylactic Total Gastrectomy (PTG): Clinicopathological Outcomes and Long-term Impact on Weight and Health-Related Quality of Life

Authors: Hui Jun Lim[1], BMed/MD, Maria O'Donovan[2], FRCPath, Claire Lamb[3], MNutr, Sophie Samra[1], BSc Adult Nursing Nyarai Chinyama[3], MSc Advanced Clinical Practice, Paul C Fletcher[4], MD, PhD, Hisham Ziauddeen[4], MRCPsych, PhD, Ju Yi Tai[5], Patrick Murphy[5], Richard H Hardwick[3], Massimiliano Di Pietro[1], MD, PhD, Rebecca C Fitzgerald[1], MD, PhD, J Robert O'Neill, FRCSEd, PhD[3, 6*]

[1]Early Cancer Institute, University of Cambridge, Cambridge, United Kingdom

[2]Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

[3]Cambridge Oesophago-gastric Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

[4]Department of Psychiatry, University of Cambridge, Herchel Smith Building, Addenbrooke's Hospital, Cambridge, CB2 0SZ, United Kingdom

[5]University of Cambridge, Cambridge, United Kingdom

[6]University of Cambridge Department of Surgery, Box 202, Addenbrookes Hospital, Hills Road, Cambridge, CB2 0QQ, United Kingdom

*Corresponding author

Correspondence to:

Dr J Robert O'Neill

University of Cambridge Department of Surgery

Box 202, Addenbrookes Hospital, Hills Road, Cambridge, CB2 0QQ

ro317@cam.ac.uk (ORCID 0000-0003-2230-7137)

Word count: 4939 words

Declarations

- **Ethics approval and consent to participate**

  Consent was obtained prospectively from all and this study was carried out under the approval of Anglia and Oxford Medical Research Ethics Committee with reference number 97/5/32 and any amendments approved by the Cambridgeshire Research Ethics Committee

- **Consent for publication**

  Not applicable.

- **Availability of data and materials**

  Data are available from the corresponding author on reasonable request.

- **Competing interests**

  The authors declare that they have no competing interests.

- **Funding**

  Lim HJ is a PhD student on the Research Training Fellowship funded by National Medical Research Council, Singapore. Di Pietro M is funded by the UK Medical Research Council and received additional funds from the Cancer Research UK Cambridge Centre (grant number CTRQQR-2021\100012). O'Neill JR acknowledges the support of the Cancer Research UK Cambridge Centre Thoracic Cancer programme (CTRQQR-2021\100012). This work was supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

- **Authors' contributions**

  Hui Jun Lim, Claire Lamb, Sophie Samra, Nyarai Chinyama, Maria O'Donovan, Richard H Hardwick and J Robert O'Neill assisted with participant recruitment and data collection. Paul C Fletcher and Hisham Ziauddeen facilitated the set-up of data collection. Ju Yi Tai and Patrick Murphy aided in data collection. Lim HJ and O'Neill JR performed data analyses and wrote the manuscript. Di Pietro M and Fitzgerald R contributed intellectual guidance and examined the manuscript critically for publication. All authors have reviewed and approved the final manuscript.

- **Acknowledgements**

  We would like to thank Marc Tischkowtiz and Samantha Grimes for their contributions and involvement in the care and follow-up of patients. In addition, we would like to thank Nikos Demiris for his guidance in the statistical analyses.

Key Points

Question: What are the clinicopathological and long-term impact on weight and health-related quality of life outcomes for patients with hereditary diffuse gastric cancer who undergo prophylactic total gastrectomy?

Findings: In this study which included 60 patients with HDGC who underwent PTG, there was a lower major complication rate at <2% and the majority of patients at 88.0% had pT1a on gastrectomy specimens. Partial weight regain was seen in those with normal pre-operative BMI between 2 to 5 years and QOL worsened markedly at 1 to 3 months but largely returned to baseline by 12 to 24 months and remained stable at baseline levels beyond 10 years.

Meaning: PTG can be undertaken with a low major complication rate and most QOL domains return to baseline within 24 months and sustained in the long-term within the context of a specialist multidisciplinary service.

Abstract

Importance:

Hereditary diffuse gastric cancer (HDGC) is predominantly due to germline *CDH1* variants and confers a high lifetime risk of diffuse gastric cancer (DGC). Prophylactic total gastrectomy (PTG) is thought to prevent DGC but has potential long-term functional, nutritional and quality-of-life (QOL) sequelae.

Objective:

We report the clinical, pathological and long-term weight and QOL outcomes from a prospective cohort of patients with HDGC who underwent PTG.

Design and Setting:

This is a single-centre prospective cohort study (Familial Gastric Cancer Study) of *CDH1* pathogenic variant carriers managed at Addenbrooke's Hospital (2005–2024).

Participants:

All patients who had *CDH1* pathogenic variants and completed at least 2 QOL questionnaires were included.

Intervention:

All patients who underwent PTG or endoscopic surveillance were included.

Main Outcomes and Measures:

The clinical, pathological, weight and QOL outcomes for patients undergoing PTG (n=60) are reported. The QOL of patients undergoing endoscopic surveillance only (n=25) and surveillance followed by PTG were also reported. Longitudinal changes in QOL were analysed using linear mixed models with Bonferroni-Holm correction.

Results:

Median age at PTG was 31 years (IQR 25–41); 75% underwent vagal-sparing PTG. The major complication rate was <2% with no operative mortalities and a median hospital stay of 8 days. Foci of intramucosal signet ring cell (SRC) carcinoma (pT1a) were seen in 88%, pT0 in 10% with a median number of SRC foci of 8. The disease-specific and overall-survivals was 100% with a median follow-up of 9.7 years. Weight loss was universal, reaching ~15% at 3 months and extending to 20% by 24 months. Partial weight regain was, however, seen in those with normal pre-operative BMI between 2–5 years. QOL worsened markedly at 1–3 months but largely returned to baseline by 12–24 months and remained stable at baseline levels beyond 10 years. Younger patients (<35) had better role functioning (p=0.038) and men reported greater persistent appetite loss (p=0.030) following PTG.

Conclusions and Relevance:

PTG can be undertaken with a low major complication rate, and is a curative treatment for HDGC. Although substantial early functional and weight effects occur, most QOL domains recover to baseline by 12–24 months and are sustained long-term with regular follow-up within a specialist multidisciplinary service.

Keywords: Hereditary diffuse gastric cancer; prophylactic total gastrectomy; quality of life; weight outcomes

Background

Hereditary diffuse gastric cancer (HDGC) syndrome is predominantly attributed to germline *CDH1* mutations.[1, 2] Individuals with pathogenic germline *CDH1* mutations have a 33.5 fold increased risk of developing diffuse gastric cancer by the age of 30 and women with HDGC carry a 6 fold higher risk of lobular breast cancer.[3] Although recent advances in genetic testing and risk assessment have facilitated the identification of *CDH1* mutation carriers, the specific mechanisms by which *CDH1* or other essential genes contribute to the pathogenesis of HDGC is poorly understood. This hampers preventative options and the insidious onset and very poor prognosis of advanced diffuse gastric cancer means that prophylactic total gastrectomy remains the only definitive option for patients with HDGC.[4-7] Current international guidelines recommend that PTG be offered to carriers of pathogenic *CDH1* mutations, but endoscopic surveillance now allows the timing of this to be individualised.[7, 8] PTG is definitive but may produce long-term functional and nutritional sequelae that affect health-related quality of life (QOL).[9]

As patients with HDGC are generally asymptomatic and may not develop cancer during their lifespan, understanding the surgical risks and long-term outcomes are essential to inform decisions surrounding surgery.[10, 11] Most published QOL data after total gastrectomy derive from patients treated for invasive disease and are either limited to short-term follow-up or are confounded by concordant cancer treatment.[12, 13] An exemplar study in patients with sporadic gastric cancer reported a decline in QOL was still present at 5-years post-operatively due to symptoms and financial consequences highlighting the need for long-term assessment.[14]

To date, there are only several retrospective studies with the majority evaluating post-operative and QOL outcomes of HDGC patients up to 2 years following PTG.[15-19] Taken

together, these studies have shown that PTG is a safe procedure with a low major complication rate and achieves robust oncological outcomes. The majority of functioning outcomes and symptoms resolve by 2 years. However, there are a few symptoms which persist and do not recover, including eating restrictions, diarrhoea, fatigue and reflux.[16-18] Notably, there is only 1 study from University of British Columbia which has assessed QOL outcomes for more than 5 years following PTG and reported there was no significant difference seen at different timepoints post-operatively.[19] However, the comparison of scores was between 3 different intervals following PTG and there was no comparison to a baseline score. Hence, these findings reinforce the need to evaluate clinical and long-term QOL outcomes following PTG.

We therefore examined the clinicopathological outcomes in patients with HDGC participating in the prospective Familial Gastric Cancer cohort study and undergoing PTG at a national referral centre.

Materials and Methods

Patient Cohort

All patients with HDGC managed as part of a national referral service at Cambridge University Hospitals from 1st January 2005 to 31st January 2025 and who were prospectively enrolled in the longitudinal Familial Gastric Cancer study (FGCS) were included. Patients in the FGCS provided written informed consent to the use of clinicopathological data and weight outcomes as well as completion of serial questionnaires. Research Ethical approval for the FGCS was provided by the Anglia and Oxford Medical Research Ethics Committee (reference number 97/5/32) and subsequent amendments approved by the Cambridgeshire Research Ethics Committee. All patients consented to the study received a baseline

endoscopy with high resolution white light endoscopy and narrow band imaging with magnification followed by targeted biopsies of visible lesions, with particular focus on pale areas and random gastric biopsies were taken according to the Cambridge protocol. For patients who opted to undergo endoscopic surveillance, 6-monthly or annual surveillance was performed depending on endoscopy findings. Patients diagnosed with invasive disease on baseline endoscopy were excluded from this report and underwent cancer staging and treatment as appropriate.

There were several factors taken into account in the decision-making for PTG, including age, co-morbidities, family history, burden of SRC foci on endoscopy and patient choice. All patients were discussed at a multidisciplinary meeting with input as needed from a clinical geneticist, gastroenterologist, upper gastrointestinal surgeon, psychiatrist, clinical psychologist, dietician and specialist nurse before proceeding with PTG. All patients proceeding to PTG underwent baseline endoscopy and extensive pre-operative counselling and prehabilitation with a team comprising a surgeon, a specialist dietician, specialist nurse, physiotherapist and in selected cases a clinical psychologist. Selective use of pre-operative CT was applied based on patient factors. All patients were planned to undergo a standardised QOL assessment at the required timepoints which were pre-operatively (baseline), 1 month, 3 months and annually post-operatively. Following PTG, patients were followed up by a multi-disciplinary team, including an upper gastrointestinal surgeon, specialist nurse and dietician. Regular assessments of patients' nutritional status, diet, weight and symptoms were performed in conjunction with dietician input and oral supplementation or rarely nasojejunal enteral feeding if required due to nutritional failure. Surgical feeding jejunostomies were not placed at PTG.

Patients who continued under endoscopic surveillance underwent 6-monthly, annual or 2-yearly endoscopic surveillance depending on various factors, including age, endoscopic findings and patient's preference, following discussion with their gastroenterologist and with input as needed from the multi-disciplinary team.

Surgical Approach and Peri-operative Protocol

All patients underwent PTG by the open approach via either midline or rooftop incision with one of two specialised upper gastrointestinal surgeons. Lymphadenectomy was D1 as per international guidance with some D0 cases in the early cohort and D2 selectively based on patient factors. The posterior vagal trunk and coeliac innervation was preserved where possible but the anterior vagal trunk was ligated at the hiatus. An end to side circular stapled oesophagojejunostomy and side to side semi-mechanical jejuno-jejunostomy was performed in all cases with intra-operative confirmation of complete gastric mucosal resection before anastomosis. Cholecystectomy was undertaken at the same procedure if gallstones were identified pre-operatively. Analgesia was via epidural or surgically placed rectus-sheath catheters with intravenous patient-controlled opiate analgesia. Patients followed a standardised enhanced recovery pathway with a planned level 2 ward stay for 1 to 2 days and then were managed on a level 0 ward for the remainder of their in-patient stay. Nasogastric tubes were not used and surgical drains only placed very selectively.

Surgical and Post-operative Outcomes Assessment

Prospectively collected clinical, pathological and post-operative outcomes were maintained using a bespoke online database. Peri-operative outcomes included operative approach, duration, lymphadenectomy, duration of high dependency and total inpatient stay duration and post-operative complications. Complications within 30 post-operative days were reported

according to the Gastrectomy Complications Consensus Group (GCCG) classification and using the Clavien-Dindo system with major complications defined as Clavien-Dindo IIIa or greater.[22,23] Post-operative mortality was regarded as within in-patient stay or 90 days. For survival analysis the interval from date of surgery to date of disease recurrence was defined as the disease-free interval and date of surgery to death from any cause as the overall survival interval, censoring at last follow-up date.

Processing and Histopathological Assessment of Gastrectomy Specimen

Gastrectomy specimens were opened along the greater curve, pinned fresh onto cork boards and then fixed for 24 hours in formalin. Subsequently, they were embedded and alternate blocks were used for diagnostic and research purposes. Histopathological data included pathological type, tumour location, size and number of signet ring cell foci and in-situ signet ring cells, proximal and distal resection margin, completeness of excision of gastric mucosa, total number of lymph nodes harvested, number of positive lymph nodes and tumour-node-metastasis (TNM) staging summarised according to the TNM staging of the 8th edition of American Joint Committee on Cancer (AJCC).[24] Histological types were classified according to the 2019 World Health Organization classification of tumours of the digestive system.[25]

Weight Outcomes Assessment

Pre-operative weight was prospectively collected when patients were scheduled for surgery and used as the baseline to derive post-operative changes in weight and body mass index (BMI; defined as weight (kg)/ height^2 (m)). Standard post-operative follow-up intervals included 2 and 6 weeks, 3, 6, 9 and 12 months and then 6 monthly intervals until the third post-operative year and annually following this or at sooner intervals if needed. Post-operative weight was recorded over various time-points during follow-up at annual face-to-

face appointments or in later follow-up via self-reporting using a secure electronic health care record messaging system.[26]

Health-related Quality of Life Assessment

We prospectively assessed the long-term impact of PTG on QOL using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-STO22 questionnaires which are both widely validated in patients having gastrectomy.[20, 21] The QLQ-C30 questionnaire comprises five functional scales, three symptom scales, six single symptom items and a global health-related QOL score.[20] Patients are assessed to have higher levels of functioning when they score higher on the functional scales and global health-related QOL score. On the contrary, patients who are experiencing more symptoms at the time of assessment would reveal higher scores on the symptom items. The EORTC QLQ-STO22 is a validated measure of health-related QOL for patients with gastric cancer.[21] It consists of 22 questions scored on a 4 or 7-point Likert scale covering five scales, including dysphagia, pain or discomfort, dietary restrictions, upper gastrointestinal symptoms, and specific emotional problems, and three single questions pertaining to dry mouth, body image and hair loss. Written or electronic responses to both questionnaires were requested prospectively at post-operative months 1, 3, 12 and annually thereafter. Raw questionnaire responses were used to derive scores for QLQ-C30 and QLQ-STO22 using the approach in the EORTC scoring manual.[27, 28] For patients continuing endoscopic surveillance, prospective questionnaire responses were requested at their baseline endoscopy and annually at subsequent endoscopies. For analysis of changes in QOL during surveillance, the first questionnaire response during surveillance was taken to be the surveillance baseline (dynamic baseline). The QOL assessment immediately prior to surgery was taken as the baseline for relative analysis of changes following PTG.

Statistical Methods

Continuous variables were summarised using median (interquartile or total range as described), and categorical variables by frequency (%). The EORTC QLQ-C30 and QLQ-STO22 scores were summarised using mean (95% confidence intervals). To account for inter-subject variance in baseline and subsequent QOL measures, the percentage change from baseline was used for subsequent statistical analyses. Longitudinal QOL changes were analysed using linear mixed models with time, age grouped as <35 or >35, sex and vagal-sparing status as fixed effects and patient as a random effect.[29] First-order autoregressive covariance was selected for residuals. Bonferroni–Holm correction accounted for multiple comparisons. A random intercept for center was included to account for within-center clustering. To compare between different models, the Bayesian information criterion (BIC) was used and the model with the lowest BIC value was used to ensure robustness of the model. A two-sided $P<0.05$ indicated statistically significant. Analyses were performed in the R statistical environment, version 4.4.1 (R Foundation) and Jamovi, version 2.7.[30, 31]

Results

Patient Characteristics and Clinicopathological Outcomes

The patient characteristics, clinical and histopathological outcomes of patients who underwent endoscopic surveillance and PTG are shown in Table 1. An overview of the clinical pathway is shown in Figure 1. A total of 60 patients underwent PTG within the study period with a median age at surgery of 31 years old (25, 41) and 45% (27/60) were female. Within the PTG cohort, there were 24 patients who initially opted for endoscopic surveillance and underwent at least 1 surveillance endoscopy and then proceeded to PTG with a median number of 3 surveillance endoscopies over a median of 18 months. All patients having PTG had pathogenic *CDH1* variants. There were 3 patients who

underwent endoscopic surveillance followed by PTG who completed at least 2 pre-operative and 2 post-operative QOL questionnaires.

The median operative time for PTG was 149 minutes (IQR 131, 234), and 45 patients (75.0%) underwent posterior vagal-sparing total gastrectomy. A total of 44 (73.3%) underwent D1 and lymphadenectomy. A single patient had a major complication with an anastomotic leak from the jejuno-jejunal anastomosis diagnosed on post-operative day 9 requiring re-operation (Clavien-Dindo IIIb). There were no post-operative mortalities. The median length of high dependency stay was 2 days (range 0 to 5) with a median total inpatient stay of 8 days (range 5 to 17).

Table 1: Summary of Patient Characteristics of Surveillance Cohort with QOL Data and Prophylactic Total Gastrectomy (PTG) Cohort, and Histopathological and Surgical Outcomes, 2005 to 2025

Characteristic	**Overall N**	
	60 (100%)[1]	**25 (100%)**
Cohort	**Surgery**	**Endoscopic Surveillance**
Age at Surgery/ Baseline Endoscopy (Years)	31 (25, 41)	36 (27, 45)
Gender		
Male	33 (55%)	12 (48.0%)
Female	27 (45%)	13 (52.0%)
Germline *CDH1* Variant		
Pathogenic	60 (100.0%)	18 (72.0%)
Truncating	19 (31.7%)	6 (24.0%)

Frameshift	13 (21.7%)	3 (12.0%)
Deletion	10 (16.6%)	3 (12.0%)
Splice site	12 (20.0%)	6 (24.0%)
Missense	6 (10.0%)	0
Likely pathogenic	0	7 (28.0%)
Truncating	0	0
Deletion	0	0
Frameshift	0	2 (8.0%)
Splice site	0	5 (20.0%)
Missense	0	0
Variant of unknown significance	0	0
BMI at Surgery (kg/m²)	25.9 (22.9, 30.4)	
Operative Approach		
Open	60 (100%)	
Lymphadenectomy		
D0	12 (20.0%)	
D1	44 (73.3%)	
D2	4 (6.7%)	
Vagal-Sparing Procedure		
Yes	45 (75%)	
No	15 (25%)	
Maximum Clavien-Dindo Grade (30 Days)		

0	48 (80%)
I-II	12 (20%)
Pneumonia	6 (10.0%)
Urinary tract infection	2 (3.2%)
Cardiac dysrhythmia	1 (1.6%)
Epidural site catheter infection	1 (1.6%)
Lower limb deep venous thrombosis	1 (1.6%)
Post-operative bleed managed conservatively	1 (1.6%)
III-IVb	1 (1.7%)
V	0 (0%)
HDU Length of Stay (Days)	
Median (Q1, Q3)	2 (1, 3)
Total Length of Stay (Days)	
Median (Q1, Q3)	8 (7, 9)
pT	
T0	6 (10%)
T1a	53 (88%)
T1b	1 (1.7%)
pN	
N0	60 (100%)
Total SRC Intramucosal	
Median (Q1, Q3)	8 (1, 30)

Total SRC In Situ	
Median (Q1, Q3)	1 (0, 4)
Total Lymph Nodes Examined	
Median (Q1, Q3)	12 (7, 20)

[1]Median (Q1, Q3); n (%); SRC: Signet ring cell

Histopathological Outcomes

All patients had complete resection of gastric mucosa and an R0 resection. The final stage was pT1bN0M0 in 1 patient (1.7%) which was due to superficial submucosal invasion in 1 lesion in the PTG specimen. This represents 0.05% (1/1697) of all histopathological lesions diagnosed on gastrectomy specimens. The final pathological stage was pT1aN0M0 in 53 patients (88%) and pT0N0M0 in 6 (10%) reflecting the high rate of signet ring cell (SRC) foci in patients with pathogenic *CDH1* mutations. There were 37 patients (68.5%) who had SRC foci on their pre-operative endoscopy and on their gastrectomy specimens. Interestingly, out of the 6 patients who had no SRC foci identified in their gastrectomy specimen one (16.7%) had a single focus of SRC and 1 (14.3%) had a pagetoid in-situ signet ring cells found on a pre-operative endoscopic biopsy. The median number of SRC foci in PTG specimens was 8 but there was a wide range from 0 to 273 reflecting a wide heterogeneity in this patient group and the choice of timing for PTG. The median number of lymph nodes harvested was 12 (range 0 to 54). No peri-neural or lympho-vascular invasion was reported in any lesions. Disease-specific survival and overall survival were both 100% with a median follow-up of 9.7 years (Supplementary Figure 1).

Assessment of Long-term Weight Changes Following PTG.

The post-operative weight (kg), and BMI of 57 patients was collected over time during follow-up. Post-operative weight loss was rapid and universal reaching 15% of baseline at 3 post-operative months. This reached a plateau at between 15% and 20% total body weight loss between 12 and 24 post-operative months (Figure 2a). When stratified by pre-operative BMI, all patients lost weight by 12 post-operative months but the greatest absolute loss occurred in patients with a higher pre-operative BMI. (Figure 2b). Further, in patients with a normal pre-operative BMI, weight gain was seen between 2 and 5 years post-operatively with the majority of patients ending up in a BMI range 20-25 kg/m^2.

Health-related Quality of Life Outcomes

A summary of the EORTC QLQ-C30 and EORTC QLQ-STO22 scores in the various functional domains and symptom scales in the surveillance cohort is shown in Figure 3. As anticipated, beyond small variances in symptom and functional domain scores, all outcomes were stable over up to 3 years.

Changes in QOL from pre-operative baseline until after the first post-operative decade are shown in Figure 5. Significant changes were seen with a high rate of most symptoms and lower functional status across most domains at 1 and 3 post-operative months. Most changes had, however, resolved to baseline levels by 12 or up to 24 months. Strikingly, in long-term follow-up from 2 to beyond 10 post-operative years, patients did not report significant different functional levels from baseline. Similarly in symptom scores, recovery was noted to close to baseline at 12 or up to 24 months. A trend was noted in more prevalent symptoms relating to appetite loss, eating difficulties, diarrhoea, reflux and fatigue although in this analysis no significant difference from baseline could be observed at 1 years onwards to greater than 10 post-operative years (Figure 3). In our experience, these symptoms are all

commonly reported in patients following total gastrectomy. A trend was also noted in reduced anxiety over time although this did not reach significance compared to baseline levels.

The changes in QOL outcomes for patients undergoing PTG according to age at the time of surgery (Supplementary Figure 2), gender (Supplementary Figure 3) and posterior vagal-sparing or non vagal-sparing surgery (Supplementary Figure 4). There were no significant differences in the majority of the functioning domains between age-groups, genders or vagal-sparing or non vagal-sparing surgery. However, it was observed that younger patients (<35) had significantly better role functioning than older patients and this persisted throughout follow-up **(p-value = 0.038)**. Following PTG, most symptom changes were similar between genders however, men experienced significantly more appetite loss compared to women and this also persisted in long-term follow-up (**p-value = 0.030**). A summary of the various functional domains and symptoms which were affected over time following surgery and in different subgroups is shown in Supplementary Figure 5.

We next sought to examine absolute QOL score changes in the same patients directly from surveillance through PTG and then into follow-up (Supplementary Figure 6). Unfortunately, only 3 patients had completed >1 QOL measure during surveillance and then proceeded to PTG and completed QOL measures during follow-up. Despite this, the short-term impact of PTG and then resolution of symptoms and functional impairment can be clearly seen at 12 to 24 post-operative months.

Discussion

This study has demonstrated that for patients who undergo PTG within the context of a specialist service, excellent outcomes can be achieved with a major complication rate of <2%, no post-operative mortalities and with a median post-operative length of stay of 8 days. These outcomes are highly favourable in comparison with many other large cohorts of patients having total gastrectomy and also compare favourably with the largest single centre experience of 150 patients undergoing PTG reported from the NIH group with a post-operative major complication (Clavien-Dindo grade of ≥3) of 11.3%, the most common being anastomotic leak at 7.3%.[17] The benchmark cohort from a global multi-centre analysis of total gastrectomy outcomes also showed a median length of inpatient stay of 10 days and major complication rate of 10.8%, the most common being pulmonary complications and anastomotic leak at 3.8% and 3.0% respectively.[23] In line with these findings, a study from the Memorial Sloan Kettering Cancer Center cohort reported a major complication rate of 16% and anastomotic leakage requiring intervention was 3%.[18] Likewise, a systematic review involving a total of 353 from 15 studies reported the most common complications were wound infection at 4.8% followed by anastomotic leak and pulmonary complications at 4.5% each.[32] In keeping with outcomes for other specialist centres offering PTG, the vast majority of patients in our study had a final pathological stage of pT1aN0M0 (88.0%) and no lymph node metastases were identified in any patients. In addition, complete gastric mucosal resection was achieved for all patients. Similarly, the cohort from NIH reported that majority of patients at 88.0% had stage Ia (pT1aN0) multi-focal SRC, 5% and 7% of patients had a pathologic diagnosis of pTisN0 and no foci of signet ring cell carcinoma identified respectively in the gastrectomy specimen.[17] Notably, there was 1 patient in our cohort who had SRC foci on endoscopy and yet had no lesions found on their gastrectomy specimen. Although extensive pathological assessment is performed for PTG specimens, only alternate blocks of the stomach were examined histologically and approximately 50% of the gastric

mucosa will be assessed. Hence, there is a possibility of SRC foci in regions of the stomach which were not sampled. Nonetheless, we predict these patients likely have a very low number of SRCC. In support of this, our long-term follow-up confirms a disease-specific survival of 100% with a median follow-up interval of 9.7 years. Taken together, these findings provide evidence of the success of endoscopic surveillance. This study also adds to the existing literature where the longest follow-up reported after PTG is a median of 7 years.[33] Overall, our results now confirm PTG, undertaken within a specialist programme with expert endoscopic surveillance, can be confirmed to be a curative treatment for HDGC.

Weight loss and nutritional deficiencies are important consequences of PTG. We are now able to report the long-term consequences of PTG on weight with follow-up beyond 15 years in some cases. We confirm that weight-loss is universal and most rapid in the first 3 post-operative months and this continues to a nadir between 12 and 24 months at a loss of 15-20% total body weight from pre-operative weight. These findings mirror those from other cohorts of patients having PTG[17]. We also demonstrate that the greatest weight loss is seen in patients with a high pre-operative BMI of above 30. These findings are very similar to those from the MSKCC cohort with the greatest loss seen in the pre-operatively obese group at a median of 28% at 2 years followed by 18% among overweight patients and 14% among those of normal weight.[18]. Several potential causes of weight loss include appetite loss, restriction due to roux limb size, dumping syndrome, pancreatic exocrine insufficiency and small intestinal bacterial overgrowth.[34] In association with post-prandial dumping symptoms, these represent potentially treatable causes of significant weight loss after PTG. We are also able to demonstrate that weight regain was possible and occurred 2 to 5 years post-operatively in the pre-operatively normal BMI group. This novel finding provides some reassurance that some of the consequences of PTG are reversible. We predict these observations may in part be

attributed to the specialist dietetic input provided for these patients and regular follow-up of their nutritional status and weight with intervention for those patients with persistent nutritional compromise.

We prospectively assessed the impact of PTG on health-related QOL using the validated EORTC QLQ-C30 and STO22 instruments. We demonstrate the most significant deviations were in the first three post-operative months across and were wide ranging across almost all assessed symptoms, functional domains and global health status. Notably, however, improvements were seen from 3 months to 12 months in physical and role functioning as well as global health status. Although global health status required a longer duration to achieve a level comparable to baseline, there was a gradual improvement over time, and remained stable over 10 year follow-up.

Several symptoms which were affected in the short-term of up to 1 year included appetite loss, eating, fatigue, nausea and vomiting and taste. There are a few of these symptoms that may be associated with dumping syndrome which occurs most frequently in the first 3 years following surgery.[35] These findings are similar to those reported from the NIH cohort which examined QOL outcomes in 126 patients undergoing PTG. The authors reported QOL scores decreased at 1 month after PTG and returned to baseline by 6 to 12 months with a median follow-up of 24 months.[17] Our finding that the recovery of symptoms and functional outcomes is preserved over a decade out from surgery is novel and should provide some reassurance to future patients with HDGC contemplating PTG.

The short term impact including wide-ranging symptoms together with weight-loss likely represents a combined effect of the mechanical changes together with significant neuro-

hormonal changes following PTG. An improved understanding of the metabolic sequelae of gastrectomy may allow more specific treatments alongside dietary advice to help mitigate the early changes, such as acarbose, somatostatin analogues and glucagon-like peptide 1 antagonists.[36] Similarly, better diagnostic tools and early recognition and access to early testing for common sequelae of PTG such as pancreatic exocrine insufficiency, small intestinal bacterial overgrowth, bile salt malabsorption and refractory hypoglycaemia would be beneficial for timely treatment and to improve outcomes. These include faecal elastase-1, hydrogen breath test, Tauroselcholic [^{75}selenium] acid (SeHCAT) scan and continuous blood glucose monitoring alongside a food diary which carry the potential to reduce the negative QOL impact of PTG.[37]

The assessment of health-related QOL outcomes in the surveillance cohort showed that, as expected, functional outcomes and symptoms remain stable over time. Furthermore, these findings are reinforced by the 3 patients who underwent surveillance followed by PTG and completed serial QOL questionnaires prior to surgery where functional outcomes and symptoms recover close to or return to baseline scores. For the psychosocial impact on QOL, symptoms of anxiety remained prominent in the surveillance group, while an improvement was seen in those who underwent PTG perhaps reflecting the reassurance of cancer prevention. Overall, these findings demonstrate that patients who undergo PTG can achieve comparable QOL outcomes compared to their pre-operative baseline within 2 years post-operatively and these effects are preserved in the long-term.

We next assessed the contribution of gender, age at surgery and preservation of the posterior vagal nerve on QOL outcomes in this cohort. Patients who had PTG aged 35 or younger had better role functioning compared to patients having surgery over the age of 35. This finding is

in line with the expectation that younger patients generally are able to recover over a shorter duration and return to work and daily activities. Furthermore, it is possible these patients in the younger age-group were inclined to undergo PTG and it was based on patient choice. It would be of interest in future work to assess the impact on QOL following PTG comparing patients who voluntarily chose to undergo the procedure regardless of endoscopic findings with those who were advised to for clinical reasons, including increase in number and size of lesions.

We also demonstrated that men having PTG experienced greater loss of appetite compared to women although no other significant differences in symptoms scores or functional outcomes were observed. It would be of interest to see if this finding is replicated in other future cohorts.

Our results also did not show a significant difference in QOL outcomes between vagal-preserving and non vagal-preserving surgery. A randomised controlled trial of vagus-preserving versus conventional distal gastrectomy in 163 patients showed reduced diarrhoea and appetite loss at 12 months post-surgery.[43] In addition, a randomised controlled trial reported reduced gallstone formation and significantly less post-operative gastroparesis in vagal-sparing distal gastrectomy for early gastric cancer.[44] Similarly, a meta-analysis assessed the functional consequences of vagal-sparing gastrectomy and reported a lower rate of gallstone formation and dumping syndrome, decreased weight loss and an earlier return of gastrointestinal motility.[45] Nonetheless, the evidence is less clear in the case of TG. The reduced gallstones formation is likely due to sparing of the hepatic branch of the anterior vagus which has been divided in all patients having PTG. The coeliac branches of the posterior vagus have been proposed to play a role in appetite and possibly diarrhoea and

weight loss and this provided the rationale for posterior vagal-sparing approach to PTG. The small numbers of patients with a complete vagotomy in our study may limit our powered to detect a clinical difference of vagal-sparing surgery and further we did not routinely use intra-operative nerve monitoring or neurophysiology studies to confirm the posterior trunk was functional at the end of the procedure.[44] Future work will be needed to explore the neurohormonal consequences of posterior vagotomy on PTG patients.

Our study is limited by a relatively small sample size. Nonetheless, HDGC is a rare condition and there only larger cohorts in the literature are those from the MSKCC and NIH groups[17, 18] By reliance on the EORTC instruments we also may have missed other important consequences of PTG not captured by these tools. For example, a study reported 23.5% of patients reported an employment change during the follow-up period which were often due to inability to perform work because of persistent symptoms, including fatigue, nausea and poor oral intake.[12] In addition, patients with family members affected by DGC had strong preferences for PTG and reported less regret following surgery which may have been due to heightened anxiety around the perceived cancer risk.[10] A further limitation is that we relied on voluntary reporting from patients both in surveillance and following PTG so we only captured a subset of the cohort. It is possible, therefore, we missed an important group with a negative experience who did not complete the questionnaires. The authors' regular contact and close follow-up with both patients undergoing PTG and their families suggest this is less likely. We also facilitated questionnaire completion by both online and paper format across time to encourage reporting. Lastly, our outcomes are in the context of a specialised service and it is not clear to what extent they would be replicated without specialised clinical, dietetic and nursing input in long-term follow-up.

The authors propose this study improves our understanding of the long-term consequences of PTG. A strength of this study is that the effect of total gastrectomy on symptoms and function has been determined independent of a confounding disease process or concurrent systemic treatment for cancer. Identification of individual functioning domains and symptoms which had worse outcomes in specific sub-groups of patients will allow them to be targeted specifically to facilitate recovery and QOL or to understand the physiological basis for this in future work. Notably, our findings have shown older and male patients tend to have worse outcomes in role functioning and appetite loss respectively, highlighting the need to be more watchful of certain groups at higher risk of adverse outcomes. In particular, more stringent follow-up with shorter intervals and a lower threshold for intervention may be implemented for male patients who display persistent appetite and weight loss. These findings are relevant to the wider literature as with improving oncological treatments and earlier detection for gastric cancer, the functional impact and long term consequences of surgery become more important. Addressing the underlying mechanism behind functional effects and then treating them become essential for patients.

In conclusion, our study has shown that PTG can be delivered safely with excellent clinical and pathological outcomes and patients can be reassured that they have been cured of the risk of DGC development. Endoscopic surveillance offers the opportunity to optimise patients within a pre-habilitation programme and maintain low post-operative complication rates. Furthermore, this study has provided greater insight into the trends of various aspects of QOL in the long-term at different time points following PTG in patients with HDGC. Despite the potential morbidity and functional effects of PTG for these patients, we have shown that patients are able to achieve comparable functioning outcomes to their baseline and to patients in surveillance within 12 to 24 months and these outcomes are maintained across a

decade of follow-up. These findings form a useful resource for patients contemplating PTG to understand the medium and long-term consequences of PTG.

References

1. Corso G, Pedrazzani C, Pinheiro H, Fernandes E, Marrelli D, Rinnovati A, et al. E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer. 2011;47(4):631–9.
2. Schrader KA, Masciari S, Boyd N, Wiyrick S, Kaurah P, Senz J, et al. Hereditary diffuse gastric cancer: association with lobular breast cancer. Familial Cancer. 2008;7:73–82.
3. Ryan CE, Fasaye GA, Gallanis AF, Gamble LA, McClelland PH, Duemler A, Samaranayake SG, Blakely AM, Drogan CM, Kingham K, Patel D, Rodgers-Fouche L, Siegel A, Kupfer SS, Ford JM, Chung DC, Dowty JG, Sampson J, Davis JL. Germline CDH1 Variants and Lifetime Cancer Risk. JAMA. 2024;332(9):722-729.
4. van der Sluis L, van Dieren JM, van der Post RS, Bisseling TM. Current advances and challenges in Managing Hereditary Diffuse Gastric Cancer (HDGC): a narrative review. Hered Cancer Clin Pract. 2024;22(1):21.
5. Cosma LS, Schlosser S, Tews HC, Müller M, Kandulski A. Hereditary Diffuse Gastric Cancer: Molecular Genetics, Biological Mechanisms and Current Therapeutic Approaches. Int J Mol Sci. 2022;23(14):7821.
6. Monster JL, Kemp LJS, Gloerich M, van der Post RS. Diffuse gastric cancer: Emerging mechanisms of tumor initiation and progression. Biochim Biophys Acta Rev Cancer. 2022;1877(3):188719.
7. Blair VR, McLeod M, Carneiro F, Coit DG, D’Addario JL, van Dieren JM, et al. Hereditary difuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21(8):e386–97.
8. Lee CYC, Olivier A, Honing J, Lydon AM, Richardson S, O'Donovan M, Tischkowitz M, Fitzgerald RC, di Pietro M. Endoscopic surveillance with systematic

random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study. Lancet Oncol. 2023;24(1):107-116.

9. van der Kaaij RT, van Kessel JP, van Dieren JM, Snaebjornsson P, Balagué O, van Coevorden F, et al. Outcomes after prophylactic gastrectomy for hereditary diffuse gastric cancer. Br J Surg. 2018;105:e176-82.
10. Hallowell N, Badger S, Richardson S, Caldas C, Hardwick RH, Fitzgerald RC, Lawton J. An investigation of the factors effecting high-risk individuals' decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC). Fam Cancer. 2016;15(4):665-676.
11. Gamble LA, Grant RRC, Samaranayake SG, Fasaye GA, Koh C, Korman L, Asif B, Heller T, Hernandez JM, Blakely AM, Davis JL. Decision-making and regret in patients with germline CDH1 variants undergoing prophylactic total gastrectomy. J Med Genet. 2023;60(3):241-246.
12. Gallanis AF, Gamble LA, Samaranayake SG, Lopez R, Rhodes A, Rajasimhan S, Fasaye GA, Juma O, Connolly M, Joyce S, Berger A, Heller T, Blakely AM, Hernandez JM, Davis JL. Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy. J Clin Oncol. 2024;42(4):421-430.
13. Wang WB, Song HN, Huang DD, Luo X, Cai HY, Yan JY, Chen WZ, Xing CG, Dong QT, Chen XL. Impact of Body Composition and Physical Function on Quality of Life After Gastrectomy for Gastric Cancer. Front Surg. 2022;8:832351.
14. Lee SS, Chung HY, Kwon OK, Yu W. Quality of life in cancer survivors 5 years or more after total gastrectomy: a case-control study. Int J Surg. 2014;12(7):700-705.
15. Hayat MY, Yakubu U, Jayasinghe J, Patel B. The Psychological Impact of Prophylactic Total Gastrectomy in Patients Who Are High Risk for Hereditary Diffuse Gastric Cancer: A Review of the Literature. Cureus. 2025;17(5):e84751.

16. Worster E, Liu X, Richardson S, Hardwick RH, Dwerryhouse S, Caldas C, Fitzgerald RC. The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. Ann Surg. 2014;260(1):87-93.
17. Gallanis AF, Bowden C, Lopez R, Gamble LA, Samaranayake SG, Payne C, Snyder D, Fasaye GA, Joyce S, Broesamle R, Miao N, Miettinen M, Quezado M, Kim SA, Korman L, Heller T, Blakely AM, Hernandez JM, Davis JL. Lessons learned from 150 total gastrectomies for prevention of cancer. J Gastrointest Surg. 2025;29(1):101889.
18. Vos EL, Salo-Mullen EE, Tang LH, Schattner M, Yoon SS, Gerdes H, Markowitz AJ, Mandelker D, Janjigian Y, Offitt K, Coit DG, Stadler ZK, Strong VE. Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. JAMA Surg. 2020;155(11):1050-1057.
19. Kaurah P, Talhouk A, MacMillan A, Lewis I, Chelcun-Schreiber K, Yoon SS, Huntsman D. Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery. Fam Cancer. 2019;18(4):429-438.
20. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCD, et al. The European Organization for Research and Treatment of Cancer QLQ–C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
21. Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, Rosemeyer D, Johnson CD, Alderson D; EORTC Quality of Life Group. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer. 2001;37(8):966-971.

22. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213.
23. Schneider MA, Kim J, Berlth F, Sugita Y, Grimminger PP, Sano T, Rosati R, Baiocchi GL, Bencivenga M, De Manzoni G, Nunobe S, Yang HK, Gutschow CA; GastroBenchmark Consortium; GASTRODATA Consortium. Defining benchmarks for total and distal gastrectomy: global multicentre analysis. Br J Surg. 2024 31;111(2):znad379.
24. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99.
25. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188.
26. Epic. Accessed 1 July, 2025. Retrieved from https://www.epic.com/
27. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer. 2001.
28. Gastric Cancer (Update of QLQ-STO22). EORTC Quality of Life. Accessed 1 August, 2025. Retrieved from https://qol.eortc.org/questionnaire/gastric-cancer-update-of-qlq-sto22/
29. Detry MA, Ma Y. Analyzing Repeated Measurements Using Mixed Models. JAMA. 2016;315(4):407-8.

30. R Core Team (2024). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>.
31. The jamovi project (2025). jamovi (Version 2.7) [Computer Software]. Retrieved from https://www.jamovi.org
32. Lim HJ, di Pietro M, O'Neill JR. A Systematic Review on Clinical and Health-Related Quality of Life Outcomes following Total Gastrectomy in Patients with Hereditary Diffuse Gastric Cancer. Cancers. 2024; 16(3):473.
33. Forrester JD, Foster D, Ford JM, Longacre TA, Ladabaum U, Fry S, Norton JA. Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes. Cancers (Basel). 2022;14(3):728.
34. Heneghan HM, Zaborowski A, Fanning M, et al. Prospective Study of Malabsorption and Malnutrition After Esophageal and Gastric Cancer Surgery. Ann Surg. 2015;262:803-807.
35. van Beek AP, Emous M, Laville M, Tack J. Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management. Obes Rev. 2017;18(1):68-85.
36. Craig CM, Liu LF, Deacon CF, et al. Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. Diabetologia 2017;60:531-540.
37. Roberts GP, Kay RG, Howard J, Hardwick RH, Reimann F, Gribble FM. Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery. Surg Obes Relat Dis. 2018;14(5):562-568.
38. Han DS, Ahn J, Ahn HS. Are the elderly patient's changes in the health-related quality of life one year after gastrectomy for stomach cancer different from those in young patients? Ann Surg Treat Res. 2021;100(1):8-17.

39. Clarke SA, Booth L, Velikova G, Hewison J. Social support: gender differences in cancer patients in the United Kingdom. Cancer Nursing. 2006;29(1):66-72.
40. Wright, C., Kelly, J. T., Healy, R., Musial, J., Campbell, K. L., & Hamilton, K. Lived experiences and unique psychosocial impacts following bariatric surgery in a publicly funded Australian tertiary hospital: a qualitative study. Australian Journal of Psychology. 2022;74(1).
41. Cheng Q, Xie J, Duan Y, Li J, She Z, Lu W, Chen Y. The psychological distress of gastrointestinal cancer patients and its association with quality of life among different genders. Support Care Cancer. 2024;32(6):329.
42. Gu Y, Ma X, Xin H, Xiang Z, Chen Y, He C. Navigating life after gastric cancer surgery: a qualitative exploration of the dyadic patient-caregiver perspective on quality of life outcomes. BMC Cancer. 2025;25:288.
43. Kim SM, Cho J, Kang D, Oh SJ, Kim AR, Sohn TS, Noh JH, Kim S. A Randomized Controlled Trial of Vagus Nerve-preserving Distal Gastrectomy Versus Conventional Distal Gastrectomy for Postoperative Quality of Life in Early Stage Gastric Cancer Patients. Ann Surg. 2016;263(6):1079-84.
44. Yan Z, Wei M, Zhang T, Guo J, Yu A, Liang Y, Huang Y, Cui X, Wang H, Zhou K, Dong Z, Yu W. Vagus Nerve Preservation for Early Distal Gastric Cancer With Monitoring and Indocyanine Green Labeling: A Randomized Clinical Trial. JAMA Surg. 2025;160(1):85-92.
45. Tokhi AM, George SV, Cabalag CS, Liu DS, Duong CP. Vagal Sparing Gastrectomy: A Systematic Review and Meta-Analysis. Dig Surg. 2024;41(3):147-160.
46. Muir J, Aronson M, Esplen MJ, et al. Prophylactic Total Gastrectomy: a Prospective Cohort Study of Long-Term Impact on Quality of Life. J Gastrointest Surg 2016;20:1950-8.

Figure Legends

Figure 1: Flowchart showing Pathway of Patients with Hereditary Diffuse Gastric Cancer who undergo Endoscopic Surveillance and/or Prophylactic Total Gastrectomy.

Figure 2a: Weight Loss from Pre-operative Baseline (%) following Prophylactic Total Gastrectomy.

Figure 2b: Change in Body Mass Index (BMI) following Prophylactic Total Gastrectomy in Patients Grouped by Pre-operative BMI with Normal (BMI 20 to 25), Overweight (BMI 25 to 30) and Obese (BMI >30) Groups. Lines represent best -fit lines and error bars are 95% confidence intervals of the best-fit line.

Figure 3: Change in EORTC QLQ-C30 and EORTC QLQ-STO22 Scores (mean ± 95% confidence interval) from Dynamic Baseline over Time (months) in Endoscopic Surveillance Cohort. The number of patients included at the various timepoints during endoscopic surveillance is shown below the bottom row of graphs and is representative for all the graphs.

Figure 4: Change in EORTC QLQ-C30 and EORTC QLQ-STO22 Scores (mean ± 95% confidence interval) from Baseline (pre-surgery) over Time in Patients following Prophylactic Total Gastrectomy (* = significant change from baseline ($P<0.05$)). The number of patients included at the various timepoints following PTG is shown below the bottom row of graphs and is representative for all the graphs.

Supplementary Figure 1: Disease-specific Survival of Patients with Hereditary Diffuse Gastric Cancer Patients undergoing Prophylactic Total Gastrectomy.

Supplementary Figure 2: Effect of Age at Surgery on Change in Quality of Life Scores following Prophylactic Total Gastrectomy. Points represent mean ± 95% confidence interval. Age at surgery was grouped as ≤35 years old or >35 years old to allow two similarly sized

groups. The outcome highlighted in the red box indicates a significant difference in percentage change from baseline scores between age-groups following surgery.

Supplementary Figure 3: Effect of Gender on Change in Quality of Life Scores following Prophylactic Total Gastrectomy. Points represent mean ± 95% confidence interval. The outcome highlighted in the red box indicates a significant difference in percentage change from baseline scores between genders.

Supplementary Figure 4: The Effect of Preservation of the Posterior Vagus on Change in Quality of Life Scores following Prophylactic Total Gastrectomy. Points represent mean ± 95% confidence interval.

Supplementary Figure 5: Summary of Impact of Prophylactic Total Gastrectomy on Health-related Quality of Life over Time.

Supplementary Figure 6: Comparison of Percentage Change in EORTC Scores (mean ± 95% confidence interval) for 3 Patients who underwent Endoscopic Surveillance followed by Prophylactic Total Gastrectomy.

760


Patients with germline *CDH1* variant
Baseline endoscopy (n = 151)
Excluded
No records/surveillance in other centres (n = 6)
Invasive disease (n = 3)
Signet ring cell foci (pT1a) or no disease (n = 142)
Excluded
Single endoscopy only (n = 48)
Endoscopic surveillance (6-monthly or annually) (n = 94)
n = 36
n = 24
Continued with endoscopic surveillance (n = 70)
Prophylactic total gastrectomy (n = 60)
Surgical Outcomes Assessed
Completed ≥2 QOL questionnaires (n = 25)
Completed pre-operative and ≥1 post-operative QOL questionnaires (n = 40)
Health-related QOL Outcomes Assessed (EORTC QLQ-C30 and EORTC QLQ-STO22)

(a)


Percentage Weight Loss from Baseline (%)
5
0
-5
-10
-15
-20
-25
-30
0
1
2
3
6
12
18
24
Months Since Surgery

(b)


BMI
30
25
20
0
3
6
9
12
18
24
36
48
60
Months Since Surgery
BMI Group
Normal
Overweight
Obese

↑ **Better Outcome**

↓ **Worse Outcome**




Worse Outcome
Better Outcome
Psychosocial Areas
Anxiety
Body Image
Financial Difficulties
Symptoms
Nausea and Vomiting
Constipation
Diarrhoea
Dysphagia
Taste
Eating
Reflux
Dry Mouth
Appetite Loss
Months since baseline
100
80
60
40
20
-20
-40
-60
-80
-100
12
24
36
>36



No. of Patients (n) 5 14 6 5 4 2 11

Better Outcome

Worse Outcome

Functional Domains and Global Health Status



Worse Outcome

Better Outcome

Psychosocial Areas



↑ Worse Outcome

↓ Better Outcome



No. of Months following PTG	1/3	12	24	36	48	60	72	84	96	108	120	>120
No. of Patients	30	28	24	20	16	15	21	13	13	9	6	20